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Abstract
Behçet’s syndrome (BS) is a systemic inflammatory disorder with unknown etiology. Features of 
both innate and adaptive immunity have been claimed in the pathogenesis of BS. To test the possible 
dysregulation of the NLRP3/cryopyrin (Nod-like receptor with a pyrin domain 3) inflammasome, 
as a result of mutation(s), we performed single-strand conformation polymorphism analyses and/
or sequencing of all the coding regions and intron–exon boundaries of NLRP3/cryopyrin and ASC 
(apoptosis-associated speck-like protein containing CARD) genes from Turkish BS patients and 
healthy controls. At the same time, we determined pro-inflammatory cytokine secretion profiles 
of peripheral blood cells in response to LPS treatment using ELISA. BS patients with vascular 
involvement showed significantly increased levels of TNF-α release at 2-, 4- and 8-h post-treatment 
and significantly increased IL-1β levels were detected at 2 h (P = 0.005) and 4 h (P = 0.025) (n = 10). 
We identified four mutations in the NLRP3/cryopyrin gene, V200M (n = 3/104) and T195M (n = 1/104), 
in BS patients but none in control samples. No mutations were detected in the ASC gene. The 
effect of these NLRP3/cryopyrin mutants on ASC speck assembly and IL-1β secretion was tested 
and the V200M mutant was shown to induce IL-1β secretion. Thus, it is likely that certain mutations 
in NLRP3/cryopyrin in combination with yet unknown other factors may contribute to the pro-
inflammatory cytokine profiles in BS patients.
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Introduction
Behçet’s syndrome (BS) is a systemic inflammatory disease 
with manifestations including recurrent oral and genital ulcera-
tions, and vasculitis involving the skin, mucosa, joints, eyes, 
veins, arteries, nervous and gastrointestinal systems. While 
some groups included BS among autoimmune disorders, the 
absence of specific antibodies and the episodic nature of the 
clinical findings led some authors to include BS among auto-
inflammatory diseases (1). A recent review claimed that both 
innate and adaptive immune responses play substantial parts 
in the pathogenesis of the disease (2). Elevated levels of acute 
phase proteins and recurrent inflammatory attacks are asso-
ciated with increased secretion of pro-inflammatory cytokines 
including IL-1β, TNF-α and IL-6. Both in the active and inactive 
BS patients, increased pro-inflammatory cytokine secretion 
and superoxide generation have been reported (3, 4).
Inflammasomes are multiprotein complexes controlling 
IL-1β secretion. The NLRP3/cryopyrin (Nod-like receptor 
with a pyrin domain 3)  inflammasome includes ASC (apop-
tosis-associated speck-like protein containing CARD) (TMS1/
PyCard) and procaspase-1. Interestingly, it has been shown 
that oligomers of ASC can form specks, presumably pyropto-
some complexes that can activate caspase-1 in response to 
pro-inflammatory stimuli (5).
IL-1β is a significant pro-inflammatory cytokine contrib-
uting to the establishment of the symptoms in autoinflam-
matory diseases and the NLRP3/cryopyrin inflammasome 
is the major regulator of caspase-1 activation leading to 
the cleavage of pro-IL-1β and the secretion of the mature 
cytokine (6). We hypothesized that IL-1β may be the earli-
est cytokine to be secreted; initiating the pro-inflammatory 
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state in BS attacks and that mutations in inflammasome com-
ponents might contribute to de-regulated IL-1β secretion.
In order to establish the general cytokine secretion profiles 
of newly diagnosed and untreated BS patients, we performed 
a time-dependent release study of IL-1β, TNF-α and IL-6 for 
the first time. Furthermore, we analysed for the first time the 
cytokine release profiles of BS patients falling into the mucocu-
taneous, vascular and uveitis/ocular involvement subtypes. 
Simultaneously, all of the coding regions and intron–exon 
boundaries of the inflammasome components, NLRP3/cryopy-
rin and ASC, were screened for the presence of mutations.
Methods
Patients and controls for peripheral blood stimulation and 
ELISA study
Newly diagnosed BS patients, who fulfilled International Study 
Group (ISG) criteria published in The Lancet (7) and had 
active disease, were included in the peripheral blood stimu-
lation and ELISA study. These patients were not using any 
medications at the time of blood collection and had not used 
immunosuppressives in the past. This group was defined 
as the functional study cohort. There were 51 patients (34 
men, 17 women, mean age 31.7 ± 6.5) in this group. Among 
these, 29 had mucocutaneous, 12 had eye and 10 had vas-
cular involvement. One of the patients with eye disease also 
had neurological disease. All of the patients with eye involve-
ment had active uveitis with a drop of at least two lines on the 
Snellen chart in visual acuity. Patients in the vascular group 
had deep vein thrombosis and/or pulmonary artery aneu-
rysms. Mucocutaneous patients had only skin and mucosa 
lesions.
Thirty-seven healthy controls (22 men, 15 women, mean 
age 29.1 ± 9.2) were also included. Both the controls and 
patients in this group were also included in the genetic 
screen.
Patients and controls for genetic study
A total of 50 patients who fulfilled ISG criteria and 50 controls 
(30 men, 20 women, mean age 27.4 ± 11) were screened for 
mutations in all nine coding exons of NLRP3/cryopyrin and 
three exons of ASC genes. Only for the exon 3 of the NLRP3/
cryopyrin, which is a hot spot for mutations in several autoin-
flammatory disorders, we increased the number of patients to 
104 (72 men, 32 women, mean age 34.3 ± 7.1).
Among these, 43 had mucocutaneous, 39 had eye, 6 had 
neurological and 19 had vascular involvement. Two of these 
patients had both eye and vascular involvement and one had 
both neurological and eye involvement.
This study was approved by the Bogazici University 
Institutional Review Board for Research with Human Subjects. 
Informed consent was obtained from all patients and control 
subjects.
Cell culture and ELISA
Blood samples were collected into EDTA-Vacutainer tubes 
(BD, Plymouth, UK) and within 2 h diluted 1:3 with prewarmed 
RPMI supplemented with 10% fetal bovine serum (FBS), 2 mM 
glutamine and antibiotics (Gibco, Grand Island, NY, USA). 
The diluted blood was incubated in 48-well tissue culture 
plates (0.5 ml per well) (TPP, Trasadinge, Switzerland) with 
100-ng ml−1 ultra-pure LPS (Escherichia coli 0111:B4; Alexis 
Biochemicals, San Diego, CA, USA), at 37°C in a CO2 incu-
bator (5%) for the indicated time points. Untreated cells were 
collected at the same time and tested at the 24-h time point. 
At the end of incubation, cells were transferred to microfuge 
tubes and centrifuged (Spectrafuge 16M Microcentrifuge; 
Labnet, Woodbridge, NJ, USA) at 3000 r.p.m. for 3 min and 
supernatants were aliquoted and frozen for determination of 
cytokine secretion. IL-1β, TNF-α and IL-6 levels in the super-
natants were measured by a commercially available ELISA 
kit (R&D Biosystems, Minneapolis, MN, USA) according to 
the manufacturer’s instructions. Standard curves of known 
concentrations of recombinant human cytokines were used 
to calculate the cytokine concentration (pg ml−1) in each indi-
vidual assay.
Genomic DNA isolation and screening of mutations/
polymorphisms
A modified version of salting-out method was used for the 
extraction of genomic DNA from whole blood samples. All 
coding regions including exon–intron boundaries of NLRP3/
cryopyrin (11 fragments), pyrin (two PCR reactions for exon 
2 and exon 10) and ASC (three fragments) were amplified by 
PCR using specific primers. Primer pairs are available upon 
request. Sequencing was done in MGH DNA Core Facility, 
Boston, MA, USA; Macrogen Inc., Seoul, South Korea and 
Iontek Inc., Istanbul, Turkey.
Statistical analysis
SPSS version 18 (IBM Corporation, Armonk, NY, USA) was 
used for all statistical analyses. Data were given as mean and 
standard deviation. Statistical analysis for IL-1β, TNF-α and 
IL-6 in untreated cells or those at, 2 h, 4 h, 8 h and 24 h was ana-
lysed by independent samples t-test (two tailed) and analysis 
of variance for comparison of the means in patient and con-
trols. Each treatment was performed in triplicates. The results 
were considered significant when the P value was <0.05.
Site-directed mutagenesis
NLRP3/cryopyrin V200M mutation was generated by PCR ampli-
fication of pcDNA3-NLRP3/cryopyrin wild-type (WT)-FLAG (a 
gift from Gabriel Nunez, University of Michigan,  Ann Arbor, MI, 
USA) with two sets of primers: F1 (5′-AAGAGATGAGCCGAAGT 
GGG-3′)/R1 (5′-CTTAATGGGACTCATGGGGCTCTCACACG-3′) 
and F2 (5′-CGTGTGAGAGCCCCATGAGTCCCATTAAG-3′)/R2 
(5′-CAAACTGGAAAGGAAGAAGACG-3′). R1 and F2 primers 
were complementary to each other and contained the under-
lined mutant nucleotides. Resulting PCR products were mixed in 
the same amounts after gel purification and amplified with F1/R2 
primers to obtain a final product containing the mutations. This 
fragment and pcDNA3-WT NLRP3/cryopyrin-FLAG vector were 
digested by using PmlI and SacII restriction enzymes, ligated 
using T4 DNA ligase and transformed into competent E.  coli 
TOP 10. Positive colonies for the mutation were selected by col-
ony PCR and confirmed by sequencing. All restriction enzymes 
and T4 DNA ligase were purchased from New England Biolabs 
(Ipswich, MA, USA).
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A similar protocol was applied for the generation of T195M 
mutant. In this case, F1 (5′-AAGAGATGAGCCGAAGTGGG-3′)/
R1 (5′-GGGGCTCTCACACATCTTGGTCTTGC-3′) and F2 
(5 ′ -GCAAGACCAAGATGTGTGAGAGCCCC-3 ′ ) /R2 
(5′-CAAACTGGAAAGGAAGAAGACG-3′) primer sets were 
used. The final product was digested with PmlI and SacII 
enzymes and re-ligated into pcDNA3-NLRP3/cryopyrin-FLAG 
vector. All primers were purchased from MGH Harvard DNA 
Core Facility.
Generation of pLenti-Ef1a-EGFP-ASC
The ASC gene cDNA was cloned from the pcDNA3-ASC plas-
mid (a gift from Prof. Gabriel Nunez, University of Michigan) 
into the pEGFP-C3 (Clontech, Mountain View, CA, USA) vec-
tor by restriction digestion with HindIII-EcoRI enzymes. The 
resulting enhanced green fluorescent protein (EGFP)-ASC 
fragment was cloned into the NheI-EcoR I double-digested 
pLenti-Ef1a-AKIL vector, which has a polylinker suitable for 
cloning from pcDNA3 and Clontech vector series (including 
NheI, HindIII, XbaI, EcoRI, NotI, EcoRV, NdeI restriction sites).
Lentivirus production
HEK293FT cells in 10-cm plates (TPP) were transfected with 
4-μg pLenti-Ef1a-EGFP-ASC, packaging vectors pCMVdel-
taR8.74 and pMD2.G (contains vesicular stomatitis virus-gly-
coprotein) by the calcium phosphate method. Two days after 
transfection, supernatants containing virus were filtered with 
0.45-μm filters, aliquoted and frozen at −80°C.
Transduction and stable line production
HEK293FT cells were plated 1 day before transduction. Virus-
containing vials were thawed at room temperature and mixed 
with polybrene (Sigma-Aldrich, Taufkirchen, Germany) at a 
final concentration of 4 μg ml−1. Media on cells were removed 
and virus-containing medium was added dropwise; 5 h later, 
the cells’ media were changed. One week later, the trans-
duced HEK293FT cells were serially diluted and transferred 
into 96-well plates (TPP) so that one cell or less could fall into 
each well. One of the subclones, EGFP-ASC_C8 was chosen 
for its high of GFP+/GFP− cell ratio (90%) and low frequency 
of spontaneous speck formation (<1%).
Transfection of EGFP-ASC stable lines with FLAG-NLRP3/
cryopyrin variants, quantification of ASC specks and IL-1β 
secretion
EGFP-ASC HEK293FT stable lines were plated on 6-well 
plates (TPP). On the next day, cells were transfected with 
either 20 ng of pcDNA3-FLAG-NLRP3/cryopyrin _WT, _
V200M, _T195M or _R260W or empty pcDNA3, with 50-ng 
caspase-1 and 500-ng IL-1β vectors. Transfection was per-
formed in triplicate wells for each construct and the experi-
ment was replicated three times.
Five images were captured from each well at random 
locations with an inverted fluorescence microscope (n = 15) 
(Zeiss Observer Z1; Carl Zeiss Microscopy, Thornwood, NY, 
USA). All images used for speck counting were taken under 
identical conditions. Cells were imaged with a ×10 objective. 
EGFP-ASC specks in the entire visual field were counted. 
The two-tailed unpaired Student’s t-test was employed to 
compare speck counts.
Additionally, IL-1β release by these cultured cells was 
measured in triplicates by ELISA using a commercially avail-
able IL-1β ELISA kit (R&D Biosystems).
EGFP-ASC HEK293FT cells were cultured for 24 h after 
transfection in DMEM without FBS. Then the supernatants 
were collected and the proteins were precipitated with trichlo-
roacetic acid by incubation on ice for 10 min, followed by a 
wash with acetone. Then the protein precipitates were dis-
solved in 50 μl 0.5% NP40 lysis buffer and loaded on SDS-
PAGE. The proteins were transferred to a polyvinylidene 
difluoride membrane in wet transfer for 2 h at 100 V in 4°C. 
Following 1 h blocking with 5% BSA, the membrane was 
incubated overnight at 4°C with 1:1000 anti-IL-1β antibody 
(Cell Signaling; 2022)  in 5% BSA. Then the membrane was 
incubated for 2 h at room temperature in 1:2000 anti-rabbit 
secondary antibody (Cell Signaling; 7074)  in 5% BSA and 
visualized using Lumi-Light Western Blotting Substrate 
(Roche Applied Sciences; 12015200001).
Results
Elevated levels of TNF-α secretion detected in  
LPS-stimulated BS patients’ cells
Peripheral blood cells collected from BS patients, with active 
lesions who had not received any treatment at the time of 
blood collection (functional study group), and healthy con-
trols were stimulated with LPS to establish time-dependent 
IL-1β, TNF-α and IL-6 secretion profiles (Fig.  1A–C). Mean 
IL-1β, TNF-α and IL-6 levels secreted at 2, 4, 8 and 24 h after 
stimulation with LPS, among vascular, mucocutaneous and 
ocular BS patients, and healthy controls are given in Table 1 
and shown in Fig. 1D.
BS patients with vascular involvement had significantly 
higher IL-1β levels at 2 and 4 h after LPS stimulation (P < 0.001, 
F3df = 6.59 and P = 0.039, F3df = 2.92, respectively) and higher 
TNF-α levels at 2 and 8 h after LPS stimulation (P = 0.033, 
F3df = 3.05 and P = 0.022, F3df = 3.38, respectively),  compared 
with mucocutaneous BS, ocular BS and healthy control 
groups. The levels among the mucocutaneous BS, ocular 
BS and healthy control groups were similar for these time 
points (P = 0.58, F2df = 0.58; P = 0.166, F2df = 1.84; P = 0.383, 
F2df = 0.956; P = 0.214, F2df = 1.28, respectively).
When the total group of BS patients was compared with 
healthy controls, IL-1β and IL-6 levels were not different at 
any of the time points after LPS stimulation. The BS group 
had a trend for higher TNF-α secretion at 2 h (251 ± 173 SD 
versus 178 ± 147 SD, P = 0.048), 4 h (280 ± 181 SD versus 
200 ± 164, P = 0.046) and 8 h (240 ± 178 versus 169 ± 146, 
P = 0.056) after stimulation. The values for mean IL-1β, TNF-
α and IL-6 levels secreted at 2, 4, 8 and 24 h after stimulation 
with LPS for the total BS group versus healthy controls are 
given in Table 2.
The IL-6 levels in the ocular subgroup were higher than the 
other groups, starting from 4 h post-treatment. However, the dif-
ference did not reach statistical significance, probably due to 
the limited number of patients in this subgroup (n = 7) (Fig. 1D).
The IL-1β and IL-6 levels in a few untreated samples were 
higher in some healthy controls, but the cytokine levels in 
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untreated samples were not compared since these samples 
were studied 24 h after blood collection, which might have 
resulted in spontaneous cytokine release.
Novel mutations identified in the NLRP3/cryopyrin gene
Screening of all nine exons including intron–exon boundaries 
of the NLRP3/cryopyrin gene resulted in the identification of a 
A
B
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Fig. 1. IL-1β, TNF-α and IL-6 secretion from LPS-stimulated blood cells in BS patients and healthy controls. (A) TNF-α (patients n = 51, controls 
n = 34), (B) IL-1β (patients n = 51, controls n = 36) and (C) IL-6 (patients n = 37, controls n = 30) release from BS patients’ and healthy con-
trols’ whole blood samples after LPS treatment (100 ng) analysed at 2-, 4-, 8- and 24-h post-stimulation. Untreated control at 0 h was collected 
together with 24-h treatment samples. First bar shows mean and the second mean ± 2 SD. (D) Average TNF-α (vascular n = 10, eye n = 12 and 
mucocutaneous n = 29), IL-1β (vascular n = 10, eye n = 12 and mucocutaneous n = 29) and IL-6 (vascular n = 6, eye n = 7 and mucocutaneous 
n = 21) release in BS patient subgroups compared with healthy controls.
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novel T195M mutation in one and V200M (V198M) mutation in 
three patients among 104 BS patients, whereas no mutations 
were found in 49 healthy controls (Fig. 2A). Patients bearing 
the V200M mutation are from either the eye, mucocutaneous 
or neurological subgroups, whereas the patient with T195M 
belongs to the mucocutaneous subgroup.
In order to check whether the V200M mutation exists in 
healthy family members, we sequenced the available genetic 
material from two brothers and a grandmother in one BS 
patient carrying the mutation and who had eye involvement. 
The V200M mutation was not detected in the tested healthy 
individuals (Fig. 2B).
Only one of the V200M carrier patients in the mucocuta-
neaous subgroup was suitable for the functional cytokine 
study, since the other two were already being treated for the 
disease. In this patient, IL-1β secretion levels were higher 
than the average values for the whole functional study group 
at 2 and 4 h and only at 2 h compared with the mucocutane-
ous subgroup (Table 3).
Interestingly, the Q705K (rs35829419) (HapMap-CEU %11, 
Hapmap-JPT %0) polymorphism in the NLRP3/cryopyrin gene 
appears with an increased frequency in both Turkish controls 
(n  =  16/116) and BS patients (n  =  13/109). Other polymor-
phisms especially in the NOD/NACHT/NAD domain of NLRP3/
cryopyrin were found as a result of sequencing (Table 4). When 
analysed statistically, the frequency differences in patients and 
controls do not appear to be significant. However, the H260H 
(1526 C→ T) polymorphism that we find in 1/49 controls has not 
been reported to date. In our study, we did not find changes in 
any of the three exons and intron–exon boundaries of the ASC 
in 50 BS patients and 50 unrelated controls tested.
Besides NLRP3/cryopyrin exons, we wanted to see 
whether mutations in the inflammasome regulatory protein 
PYRIN may be involved in BS, so we sequenced a subset 
of patients with high IL-1β secretion levels and/or carrying a 
mutation in NLRP3/cryopyrin for MEFV exon 10 (n = 26). Five 
patients have the M694V mutation (19.2%), previously linked 
with familial Mediterranean fever, one has M680I and another 
one has A744S. The V200M patient with neurological disease 
also has a MEFV M694V mutation.
Mutant NLRP3/cryopyrin’s effect on ASC speck formation
We studied whether V200M and T195M NLRP3/cryopyrin 
over-expressing cells are more prone to ASC speck forma-
tion in comparison with WT NLRP3/cryopyrin-expressing 
cells. EGFP-ASC stable HEK293FT cells were transfected 
with equal amount of FLAG-NLRP3/cryopyrin_WT, _V200M, 
_T195M or _R260W plasmids and the number of speck for-
mation in five representative visual fields from three different 
wells were counted under identical settings of the inverted 
fluorescent microscope (Fig. 3A and B).
As expected, we observed that transfection of 20 ng of WT 
NLRP3/cryopyrin induced speck formation (average number 
of specks per visual field= 17.6 ± 5.6) significantly, compared 
with control empty pcDNA3-transfected cells (9.2 ± 2.4, 
Table 1. Cytokine secretion profiles of BS patient subgroups
Time IL-1β TNF-α IL-6
Mucocutaneous 
(n = 29)
Eye  
(n = 12)
Vascular 
(n = 10)
Mucocutaneous 
(n = 29)
Eye  
(n = 12)
Vascular 
(n = 10)
Mucocutaneous 
(n = 21)
Eye  
(n = 7)
Vascular 
(n = 6)
Untreated 10 ± 18 12 ± 17 12 ± 28 8 ± 22 12 ± 25 11 ± 26 12 ± 18 28 ± 52 13 ± 32
2 h 68 ± 98 37 ± 43 210 ± 187** 223 ± 161 238 ± 153 358 ± 207* 53 ± 46 59 ± 82 47 ± 30
4 h 300 ± 315 188 ± 178 611 ± 474* 250 ± 161 285 ± 205 369 ± 202 136 ± 105 211 ± 330 164 ± 132
8 h 399 ± 436 381 ± 407 606 ± 461 198 ± 152 264 ± 206 348 ± 189* 154 ± 94 271 ± 338 147 ± 128
24 h 352 ± 391 354 ± 386 509 ± 489 124 ± 117 137 ± 123 213 ± 137 163 ± 107 229 ± 259 170 ± 147
IL-1β, TNF-α and IL-6 secretion from LPS-stimulated blood cells in subgroups of BS patients. Results are given as means in pg ml−1 ± standard 
deviations.
*P value <0.05, **P value <0.001.
Table 2. Cytokine secretion profiles of BS patients and healthy controls
Time IL-1β TNF-α IL-6
Patients (n = 51) Controls (n = 36) Patients (n = 51) Controls (n = 34) Patients (n = 37) Controls (n = 30)
Untreated 11 ± 20 154 ± 226 10 ± 23 18 ± 22 16 ± 31 74 ± 104
2 h 88 ± 125 60 ± 72 252 ± 173* 178 ± 148 53 ± 49 45 ± 78
4 h 333 ± 350 393 ± 363 303 ± 25* 200 ± 164 156 ± 166 119 ± 123
8 h 432 ± 433 449 ± 449 241 ± 179* 162 ± 142 175 ± 174 149 ± 133
24 h 384 ± 407 470 ± 469 145 ± 125 117 ± 118 177 ± 152 204 ± 206
IL-1β, TNF-α and IL-6 secretion from LPS-stimulated blood cells in BS patients and healthy controls. Results are given as means in pg ml−1 ± 
standard deviations.
*P value <0.05.
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P < 0.0001). On the other hand, transfection of R260W mutant 
NLRP3/cryopyrin, previously reported to cause spontaneous 
IL-1β release in over-expression studies, increased speck 
numbers significantly (109.4 ± 48.3 specks) compared with 
WT NLRP3/cryopyrin-transfected cells. Besides, T195M 
mutant NLRP3/cryopyrin-transfected cells have a slight but 
significant decrease in the number of specks (12 ± 6) in com-
parison with WT NLRP3/cryopyrin-transfected cells, whereas 
V200M mutant NLRP3/cryopyrin-transfected cells did not 
form a significantly higher number of specks (25.3 ± 13.4) 
(Fig. 3B). NLRP3/cryopyrin expression was verified for each 
condition (Fig. 3D). These data suggest that, unlike R260W, 
the T195M and V200M mutant NLRP3/cryopyrin proteins do 
not have a pronounced positive effect on ASC oligomerization.
Mutant NLRP3/cryopyrin’s effect on IL-1β secretion
Any effect of NLRP3/cryopyrin mutants on IL-1β secretion was 
tested in the EGFP-ASC HEK293FT stable line (Fig. 3C). As 
expected, transfection of the R260W mutant increased IL-1β 
secretion significantly (196 ± 33.6 pg ml−1, P < 0.0001) com-
pared with WT (24.77 ± 2.57 pg ml−1; 0.81 ± 1.2 pg ml−1 for empty 
plasmid-transfected cells, Fig.  3C). V200M also increased 
IL-1β release (65.93 ± 6.9 pg ml−1, P < 0.0001), whereas the 
T195M mutation decreased IL-1β release (8.01 ± 6.21 pg ml−1, 
P < 0.0001) in comparison with WT NLRP3/cryopyrin.
Secreted mature IL-1β was also tested by western blot-
ting (Fig.  3D) and results correlate with ELISA results. 
Furthermore, the IL-1β secretion pattern is in line with the 
ASC speck formation.
Discussion
Our study shows that BS patients with vascular involvement 
have higher IL-1β and TNF-α levels after stimulation with LPS, 
compared with BS patients with eye involvement, BS patients 
with only mucocutaneous involvement and healthy controls 
(Fig. 1D). Cytokine levels of IL-1β and TNF-α in BS patients 
with eye and mucocutaneous involvement were similar to 
healthy controls (Fig. 1D). These findings reflect the clinical 
observation that BS patients with vascular involvement are 
the ones who have fever and other constitutional symptoms, 
especially during active disease. Moreover, elevation of acute 
phase reactants is also a feature of vascular BS, which alarms 
the clinician to this type of involvement.
There are several findings indicating the presence of dif-
ferent pathogenetic mechanisms underlying different types 
of organ involvement in BS. The presence of various symp-
tom clusters in BS, such as the association of deep vein 
thrombosis and superficial thrombophlebitis or the associa-
tion of acne, arthritis and enthesopathy, raises the possibility 
Fig. 2. Novel T195M mutation and other genetic changes were identified in the NLRP3/cryopyrin gene. (A) Genetic mutations and polymor-
phism found in BS patients and healthy controls. (B) Genetic analysis of a patient family with V200M mutation.
Table 3. Cytokine secretion profile of BS patient with V200M 
mutation
IL-1β TNF-α IL-6
Untreated 27.2 ± 3.9 6.9 ± 0.5 18.1 ± 0.6
2 h 289.2 ± 21.8 342.7 ± 20.9 30.8 ± 2.2
4 h 343.6 ± 24.8 274.8 ± 39.9 50.9 ± 5.9
8 h 303.0 ± 48.8 194.4 ± 3.4 55.3 ± 10.4
24 h 341.4 ± 39.8 74.0 ± 27.1 48.7 ± 5.6
IL-1β, TNF-α and IL-6 secretion from LPS-stimulated blood cells in 
a patient with V200M mutation. Results are given as means of tripli-
cates readings in pg ml−1 ± standard deviations.
NLRP3/cryopyrin and Behçet’s syndrome 77
Ta
b
le
 4
. 
Si
ng
le
 n
uc
le
ot
id
e 
po
ly
m
or
ph
is
m
s 
in
 N
LR
P3
/c
ry
op
yr
in
 e
xo
n 
3 
fo
r B
S 
pa
tie
nt
s 
an
d 
he
al
th
y 
co
nt
ro
ls
N
uc
le
ot
id
e 
ch
an
ge
s
Pa
tie
nt
s
C
on
tro
ls
To
ta
l p
op
ul
at
io
n
H
om
oz
yg
ot
e 
W
T
H
et
er
oz
yg
ot
e
H
om
oz
yg
ot
e 
va
ria
nt
To
ta
l  
va
ria
nt
H
om
oz
yg
ot
e 
W
T
H
et
er
oz
yg
ot
e
H
om
oz
yg
ot
e 
va
ria
nt
To
ta
l  
va
ria
nt
H
om
oz
yg
ot
e 
W
T
H
et
er
oz
yg
ot
e
H
om
oz
yg
ot
e 
va
ria
nt
To
ta
l  
va
ria
nt
p.
T2
21
T
82
.7
%
 
(8
6/
10
4)
16
.3
5%
 
(1
7/
10
4)
0.
96
%
 
(1
/1
04
)
17
.3
%
 
(1
8/
10
4)
83
.6
7%
 
(4
1/
49
)
16
.3
2%
 
(8
/4
9)
0%
 
(0
/4
9)
16
.3
2%
 
(8
/4
9)
83
%
 
(1
27
/1
53
)
11
.1
1%
 
(1
7/
15
3)
0.
65
%
 
(1
/1
53
)
16
.9
9%
 
(2
6/
15
3)
14
09
 
A
C
C
>
A
C
T
rs
75
25
97
9
p.
A
24
4A
18
.2
7%
 
(1
9/
10
4)
52
.8
9%
 
(5
5/
10
4)
28
.8
5%
 
(3
0/
10
4)
81
.7
3%
 
(8
5/
10
4)
12
.2
5%
 
(6
/4
9)
69
.3
9%
 
(3
4/
49
)
18
.3
7%
 
(9
/4
9)
91
.8
4%
 
(4
5/
49
)
16
.3
4%
 
(2
5/
15
3)
58
.1
7%
 
(8
9/
15
3)
25
.4
9%
 
(3
9/
15
3)
83
.6
6%
 
(1
28
/1
53
)
14
78
 
G
C
G
>
G
C
A
rs
38
06
26
8
p.
H
26
0H
10
0%
 
(1
04
/1
04
)
0%
 
(0
/1
04
)
0%
 
(0
/1
04
)
0%
 
(0
/1
04
)
97
.9
6%
 
(4
8/
49
)
2.
04
%
 
(1
/4
9)
0%
 
(0
/4
9)
2.
04
%
 
(1
/4
9)
99
.3
5%
 
(1
52
/1
53
)
0.
65
%
 
(1
/1
53
)
0%
 
(0
/1
53
)
0.
65
%
 
(1
/1
53
)
15
26
 
C
A
C
>
C
AT
N
ew
p.
R
26
2R
0.
96
%
 
(1
/1
04
)
3.
85
%
 
(4
/1
04
)
95
.1
9%
 
(9
9/
10
4)
99
.0
4%
 
(1
03
/1
04
)
0%
 
(0
/4
9)
6.
12
%
 
(3
/4
9)
93
.8
8%
 
(4
6/
49
)
10
0%
 
(4
9/
49
)
0.
96
%
 
(1
/1
53
)
4.
58
%
 
(7
/1
53
)
94
.7
7%
 
(1
45
/1
53
)
95
.4
2%
 
(1
46
/1
53
)
15
32
 
C
G
A
>
C
G
G
rs
49
25
54
3
p.
D
31
2D
97
.2
2%
 
(1
05
/1
08
)
2.
78
%
 
(3
/1
08
)
0%
 
(0
/1
08
)
2.
78
%
 
(3
/1
08
)
98
%
 
(4
9/
50
)
2%
 
(1
/5
0)
0%
 
(0
/5
0)
2%
 
(1
/5
0)
97
.4
7%
 
(1
54
/1
58
)
2.
53
%
 
(4
/1
58
)
0%
 
(0
/1
58
)
2.
53
%
 
(4
/1
58
)
16
82
 
G
A
C
>
G
AT
rs
14
38
40
03
3
p.
P3
42
P
98
.1
5%
 
(1
06
/1
08
)
1.
85
%
 
(2
/1
08
)
0%
 
(0
/1
08
)
1.
85
%
 
(2
/1
08
)
98
%
 
(4
9/
50
)
2%
 
(1
/5
0)
0%
 
(0
/5
0)
2%
 
(1
/5
0)
98
.1
%
 
(1
55
/1
58
)
0%
 
(0
/1
58
)
1.
9%
 
(3
/1
58
)
1.
90
%
 
(3
/1
58
)
17
72
 
C
C
C
>
C
C
T
rs
41
31
15
73
p.
L3
46
L
98
.1
5%
 
(1
06
/1
08
)
1.
85
%
 
(2
/1
08
)
0%
 
(0
/1
08
)
1.
85
%
 
(2
/1
08
)
96
%
 
(4
8/
50
)
4%
 
(2
/5
0)
0%
 
(0
/5
0)
4%
 
(2
/5
0)
97
.4
7%
 
(1
54
/1
58
)
2.
53
%
 
(4
/1
58
)
0%
 
(0
71
58
)
2.
53
%
 
(4
/1
58
)
17
84
 
C
TG
>
C
TA
rs
14
46
16
57
7
p.
L4
13
L
98
.1
5%
 
(1
06
/1
08
)
1.
85
%
 
(2
/1
08
)
0%
 
(0
/1
08
)
1.
85
%
 
(2
/1
08
)
10
0%
 
(5
0/
50
)
0%
 
(0
/5
0)
0%
 
(0
/5
0)
0%
 
(0
/5
0)
98
.7
3%
 
(1
56
/1
58
)
1.
27
%
 
(2
/1
58
)
0%
 
(0
/1
58
)
1.
27
%
 
(2
/1
58
)
19
83
 
C
TG
>
TT
G
rs
14
84
78
87
5
p.
S4
36
S
64
.8
2%
 
(7
0/
10
8)
26
.8
5%
 
(2
9/
10
8)
8.
33
%
 
(9
/1
08
)
35
.1
9%
 
(3
8/
10
8)
58
%
 
(2
9/
50
)
40
%
 
(2
0/
50
)
2%
 
(1
/5
0)
42
%
 
(2
1/
50
)
62
.6
6%
 
(9
9/
15
8)
31
%
 
(4
9/
15
8)
6.
33
%
 
(1
0/
15
8)
37
.3
4%
 
(5
9/
15
8)
20
54
 
TC
C
>
TC
T
rs
34
29
83
54
p.
H
46
5H
99
.0
7%
 
(1
07
/1
08
)
0.
93
%
 
(1
/1
08
)
0%
 
(0
/1
08
)
0.
93
%
 
(1
/1
08
)
10
0%
 
(5
0/
50
)
0%
 
(0
/5
0)
0%
 
(0
/5
0)
0%
 
(0
/5
0)
99
.3
7%
 
(1
57
/1
58
)
0.
63
%
 
(1
/1
58
)
0%
 
(0
/1
58
)
0.
63
%
 
(1
/1
58
)
21
41
 
C
A
C
>
C
AT
rs
11
14
00
20
8
Si
ng
le
-n
uc
le
ot
id
e 
po
ly
m
or
ph
is
m
s 
in
 B
S 
pa
tie
nt
s 
an
d 
he
al
th
y 
co
nt
ro
ls
.
78 NLRP3/cryopyrin and Behçet’s syndrome
Fig. 3. The effects of NLRP3/cryopyrin mutations on inflammasome activation. (A) ASC speck formations. Inverted fluorescent microscopy 
images of stable ASC-EGFP-expressing HEK293FT cells transfected with empty vector, FLAG-NLRP3/cryopyrin_WT, _V200M, _T195M, _R260W 
and _WT in the absence of caspase-1. ASC specks are shown with a white arrow. The images represent cells transfected with 20 ng of the 
corresponding NLRP3/cryopyrin, 50-ng caspase-1 and 500-ng IL-1β plasmids. (B) Quantification of ASC speck numbers. (C) Measurement of 
IL-1β release by ELISA. (D) Western blot of secreted mature IL-1β protein.
NLRP3/cryopyrin and Behçet’s syndrome 79
that the pathogenesis of BS involves more than one biologic 
pathway (8). This is also supported by evidence from drug 
trials. Colchicine, which is an effective drug in skin lesions 
and arthritis of BS patients, has no efficacy in eye or vascu-
lar involvement. The difference in cytokine secretion profiles 
among different types of BS patients in this study is more evi-
dence for the presence of different mechanisms in the patho-
genesis of BS.
There are controversial studies regarding the serum IL-1β 
levels (9–11) in BS patients some of which report normal and 
some elevated levels. Mege et al. (3) found increased TNF-α, 
IL-1β, IL-6 and IL-8 levels in culture conditions after stimu-
lation with LPS 16 h post-treatment, whereas Slobodin et al. 
(12) reported that TNF-α production after LPS stimulation was 
similar in BS patients and healthy controls. The advantage of 
our study is that we included only patients with active lesions 
at the time of blood collection, who had not received any 
medication including colchicine. Moreover, analyzing clinical 
subgroups separately gave us the opportunity to evaluate the 
role of each cytokine in each type of involvement.
Another novelty brought by this paper is that we studied 
the kinetics of cytokine secretion in BS patients and com-
pared this to healthy controls. This is important because not 
only the level of inflammation, but also the timing is thought to 
be important in BS. A typical example for this is the pathergy 
phenomenon, where the reaction is clinically indistinguishable 
from healthy controls in the beginning. However, after 24 h, the 
reaction begins to subside in healthy controls, in contrast to 
BS patients where the inflammation is prolonged up to 72 h. 
This was also shown in the tissue level by skin biopsies of the 
needle prick sites at 0, 8 and 48 h after the prick. Cellular infil-
tration patterns, cytokine and chemokine levels were similar in 
BS patients and healthy controls for the first 8 h. However, after 
8 h, increased influx of mature dendritic cells, monocytes and 
lymphocytes as well as increased cytokine and chemokine 
levels continued only among BS patients (13). Our study 
shows that whole blood cytokine levels after LPS stimulation 
are higher, especially for the vascular BS patients, but the 
cytokine release kinetics of IL-1β, TNF-α and IL-6 are parallel 
in BS patients and healthy controls (Fig. 1D).
A randomized controlled trial and several open studies 
showed that TNF-α antagonists are effective in the man-
agement of BS. Especially, patients with eye, neurologic 
and gastrointestinal involvement, resistant to other drugs 
have benefitted from TNF-α antagonists. Case series show-
ing efficacy of IL-1 antagonists have also been published. 
The elevated IL-6 levels that we have observed in ocular BS 
patients may be important with this respect. Elevated IL-6 lev-
els were previously shown in cerebrospinal fluid and serum of 
BS patients with neurologic involvement, another subgroup 
of patients that may sometimes be associated with ocular 
involvement. These findings point out to the possibility of 
using IL-6 antagonists in such patients (Fig. 1D).
IL-1β is a key cytokine in autoinflammatory disorders. 
Dominant mutations in the inflammasome component NLRP3/
cryopyrin have been documented to cause higher levels of 
IL-1β secretion. For instance, the R260W mutant NLRP3/
cryopyrin has been reported to cause spontaneous IL-1β 
release by monocytes isolated from Muckle–Wells syndrome 
(MWS) patients (14).
We have found three patients carrying the V200M NLRP3/
cryopyrin mutation and a novel T195M NLRP3/cryopyrin 
mutation all in the heterozygous state (Fig.  2A). V200 and 
T195 are conserved among primates and higher mam-
mals such as cows, but not in mice and rats. For one of the 
V200M mutation carriers, genetic material from healthy family 
members was tested negative for this mutation. V200M has 
been reported in one study to have an incidence of 1/97 for 
BS patients (15). None of these previous reports examines 
the functional importance of the V200M for inflammasome 
assembly. Interestingly, a clinical case report about a British 
family with three MWS patients carrying the heterozygous 
V200M mutation gave a complete response to Anakinra treat-
ment (16). This finding supports the fact that V200M might 
be important in the disease pathogenesis. However, the low 
incidence in our study and presence of the mutation in the 
healthy Caucasian populations with an allele frequency of 
0.0074 (17) make it impossible to draw strong conclusions 
about its significance in BS pathogenesis.
We investigated the functional consequence of the V200M 
and T195M mutant NLRP3/cryopyrin on inflammasome 
assembly and activation via the speck formation and IL-1β 
secretion assays. The V200M mutant tends to show a posi-
tive effect on the formation of specks, albeit not significantly 
(Fig. 3A and B), but the significant effect of this mutant on 
IL-1β secretion was confirmed by ELISA and western blot 
analyses in a more solid and quantitative manner (Fig.  3C 
and D). Although this increase in IL-1β secretion was not as 
pronounced as R260W’s effect, still V200M appears to be a 
moderately activating mutation.
Recently, the MEFV M694V mutation has been shown to be 
associated with BS in the Turkish population (18). PYRIN has 
been previously shown to activate NLRP3/cryopyrin inflam-
masome and combination of PYRIN and NLRP3/cryopyrin 
mutant proteins did not interfere with inflammasome activa-
tion (19). The presence of both NLRP3/cryopyrin V200M and 
MEFV M694V mutations in one of the four patients carrying 
NLRP3/cryopyrin mutations suggests that mutations of inflam-
masome components and/or regulators, such as NLRP3/cry-
opyrin and PYRIN, may have a combinatorial effect on the 
cytokine release profiles of BS patients. It was shown very 
recently that treatment of BS patients suffering from acute 
intraocular inflammation with XOMA 052, a humanized anti-
IL-1β antibody, resulted in reduction of inflammation in all 
seven patients, spotlighting the importance of the IL-1β path-
way in BS pathogenesis (20).
Overall, our data show that NLRP3/cryopyrin and/or ASC 
by themselves are unlikely to be responsible for BS patho-
genesis or to account for the observed a cytokine profiles. It 
is clear that BS is a complex disorder with possible involve-
ment of multiple genes and pathways (such as MEFV, HLA-
B51, MICA, etc.) along with a contribution from environmental 
factors. Mutations in proteins, such as TLR4 and TLR2, known 
to regulate the inflammation process via the NF-κB pathway, 
controlling TNF-α and pro-IL-1β levels, were recently shown 
to be associated with BS (18, 21). Besides Toll-like recep-
tors, other complexes controlling caspase-1 and caspase-5 
activation such as AIM-2, NLRC4/Ipaf and other NLRP inflam-
masomes are still plausible mutation targets that may predis-
pose individuals to develop BS.
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